Neuropeptide Y secretion from a malignant extraadrenal retroperitoneal paraganglioma

Kuvshinoff, Boris W.; Nussbaum, Michael S.; Richards, AnthonyJ.; Bloustein, P; McFadden, David W.

doi:10.1002/1097-0142(19921101)70:9<2350::aid-cncr2820700923>3.0.co;2-8

Cited by 7 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Y1R antagonist, H409/22 acetate, and Y5R antagonist, CGP71683A (Novartis International AG, Basel, Switzerland) were gifts from AstraZeneca (Mölndal, Sweden), and Y2R antagonist, BIIE0246TF, from Boehringer Ingelheim Pharma (Ingelheim, Germany). Selective receptor agonists, Y2 ([Ahy [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] ] NPY) and Y5 (cM10), were gifts from Dr. Annette Beck-Sickinger (University of Leipzig, Leipzig, Germany) and DPPIV inhibitor, P32/98, from Probiodrug (Halle, Germany).…”

Section: Methodsmentioning

confidence: 99%

“…This sympathetic neurotransmitter and its receptors are highly expressed in tumors derived from the autonomic nervous system, including those originating from sympathetic neurons (neuroblastoma and pheochromocytoma) as well as Ewing's sarcoma family of tumors (ESFT) with a putative origin from parasympathetic neurons (1)(2)(3)(4)(5). Neuroblastoma is the most common malignant disease of infancy and, along with ESFT, belongs to a group of small, blue, round cell tumors of childhood.…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest–Derived Tumors

Kitlińska¹,

Abe²,

Kuo³

et al. 2005

Cancer Research

127

212

View full text Add to dashboard Cite

Neuropeptide Y (NPY) is a sympathetic neurotransmitter recently found to be potently angiogenic and growth promoting for endothelial, vascular smooth muscle and neuronal cells. NPY and its cognate receptors, Y1, Y2 and Y5, are expressed in neural crest-derived tumors; however, their role in regulation of growth is unknown. The effect of NPY on the growth and vascularization of neuroendocrine tumors was tested using three types of cells: neuroblastoma, pheochromocytoma, and Ewing's sarcoma family of tumors (ESFT). The tumors varied in expression of NPY receptors, which was linked to differential functions of the peptide. NPY stimulated proliferation of neuroblastoma cells via Y2/Y5Rs and inhibited ESFT cell growth by Y1/Y5-mediated apoptosis. In both tumor types, NPY receptor antagonists altered basal growth levels, indicating a regulatory role of autocrine NPY. In addition, the peptide released from the tumor cells stimulated endothelial cell proliferation, which suggests its paracrine angiogenic effects. In nude mice xenografts, exogenous NPY stimulated growth of neuroblastoma tumors, whereas it increased apoptosis and reduced growth of ESFT. However, in both tumors, NPY treatment led to an increase in tumor vascularization. Taken together, this is the first report of NPY being a growth-regulatory factor for neuroendocrine tumors, acting both by autocrine activation of tumor cell proliferation or apoptosis and by angiogenesis. NPY and its receptors may become targets for novel approaches in the treatment of these diseases, directed against both tumor cell proliferation and angiogenesis. (Cancer Res 2005; 65(5): 1719-28)

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 96%

Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest–Derived Tumors

Kitlińska¹,

Abe²,

Kuo³

et al. 2005

Cancer Research

127

212

View full text Add to dashboard Cite

show abstract

“…A higher plasma level of NPY was observed in patients with metastasizing tumors than in those with benign tumors [48,49]. In a case of metastasizing extra-adrenal retroperitoneal paraganglioma, the NPY plasma level was decreased after primary tumor resection; however, its concentrations progressively increased during the postoperative period, coinciding with the documentation of metastases [50]. Conversely, decreased NPY gene expression was found in metastasizing PHEOs compared with benign ones [51,52].…”

Section: Biochemical Markersmentioning

confidence: 90%

Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas

Snezhkina

Pavlov

Dmitriev

et al. 2021

Life

View full text Add to dashboard Cite

Paragangliomas and pheochromocytomas (PPGLs) are rare neuroendocrine tumors originating from paraganglionic tissue in many sites of the body. Most PPGLs are characterized by nonaggressive behavior but all of them have the potential to metastasize. PPGLs represent a great diagnostic dilemma as it is difficult to recognize tumors that are likely to be metastasizing; criteria of malignancy can be found both in benign and metastatic forms. This review aims to analyze the current knowledge of the nature of metastasizing PPGLs paying particular attention to head and neck paragangliomas (HNPGLs). Potential predictors of the malignancy risk for PPGLs were summarized and discussed. These data may also help in the development of diagnostic and prognostic strategies, as well as in the identification of novel potential therapeutic targets for patients with PPGLs.

show abstract

Multiple neuropetide immunoreactivities in a renin-producing human paraganglioma

Fried

Wikström

Höög

et al. 1994

Cancer

View full text Add to dashboard Cite

Background. A case of a renin‐producing paraganglioma of adrenal origin with metastases to the retroperitoneal area, paravaginal area, and the ovary is reported with immunohistochemical findings indicating expression of multiple neuropeptide immunoreactivities. The patient was 23 years old at the time of diagnosis, and died from metastatic spread of the tumor 7 years later. Methods. Tumor tissue was examined by light microscopy, indirect immunohistochemistry, and electron microscopy. Results. The tumor tissue investigated contained several cells exhibiting opioid peptide‐like immunoreactivities (i. e., enkephalin and dynorphin‐like immunoreactivity [LI]). A lower number of cells displayed neuropeptide Y‐, galanin‐, somatostatin‐, neurotensin‐, substance Peptide histidine‐isoleucine‐, cholecystokinin‐, renin‐, and calbindin‐LI. Conclusion. To the authors' knowledge, galanin, dynorphin, peptide histidine‐isoleucine, cholecystokinin, and calbindin have not been reported previously to occur in paraganglioma, and renin has been reported to occur very rarely. A review of recent literature suggest that enkephalin‐, neuropeptide Y‐, and somatostatin‐like immunoreactivities may be useful as diagnostic markers for paragangliomas.

show abstract

Neuropeptide Y secretion from a malignant extraadrenal retroperitoneal paraganglioma

Cited by 7 publications

References 20 publications

Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest–Derived Tumors

Differential Effects of Neuropeptide Y on the Growth and Vascularization of Neural Crest–Derived Tumors

Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas

Multiple neuropetide immunoreactivities in a renin-producing human paraganglioma

Contact Info

Product

Resources

About